Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog. Efficacy is only moderate, and improved treatment strategies are u...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyenla, Xammy, Wehri, Eddie, Van Dis, Erik, Biering, Scott B., Yamashiro, Livia H., Zhu, Chi, Stroumza, Julien, Dugast-Darzacq, Claire, Graham, Thomas G. W., Wang, Xuanting, Jockusch, Steffen, Tao, Chuanjuan, Chien, Minchen, Xie, Wei, Patel, Dinshaw J., Meyer, Cindy, Garzia, Aitor, Tuschl, Thomas, Russo, James J., Ju, Jingyue, Näär, Anders M., Stanley, Sarah, Schaletzky, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628577/
https://www.ncbi.nlm.nih.gov/pubmed/36323770
http://dx.doi.org/10.1038/s41598-022-21034-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628577/
https://www.ncbi.nlm.nih.gov/pubmed/36323770
http://dx.doi.org/10.1038/s41598-022-21034-5

Ejemplares similares